GACM
NKTR icon

Green Arrow Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Green Arrow Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-10,667
Closed -$1.85M – 287
2013
Q2 		$1.85M Buy
+10,667
New +$1.64M 0.15% 167

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Green Arrow Capital Management's NKTR Position: Q3 2013 in Review

Green Arrow Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2013, closing a stake of 10,667 shares — an estimated $1.85M sold.

Green Arrow Capital Management first reported a position in NKTR in Q2 2013 and held it in 1 quarter. The position peaked at $1.85M in Q2 2013. 142 funds tracked by Wall St. Rank hold NKTR as of Q3 2013.

  • Green Arrow Capital Management reported no remaining Nektar Therapeutics position as of Q3 2013 after selling out during the quarter.
  • Green Arrow Capital Management sold 10,667 Nektar Therapeutics shares in Q3 2013, an estimated $1.85M.
  • Green Arrow Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 1 quarter.
  • Green Arrow Capital Management's Nektar Therapeutics position peaked at $1.85M in Q2 2013.
  • 142 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2013.

Based on Green Arrow Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.